# Treatment of Iron Overload Requiring Chelation Therapy

> **NCT01927913** · PHASE2 · WITHDRAWN · sponsor: **Shire**

## Conditions studied

- Transfusional Iron Overload
- Iron Overload
- Iron Chelation
- Beta-thalassemia
- Transfusional Hemosiderosis
- Iron Metabolism Disorders
- Metabolic Diseases

## Interventions

- **DRUG:** SPD602
- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT01927913
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-11-20
- **Primary completion:** 2015-10-30
- **Final completion:** 2015-10-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was withdrawn until the evaluation of the nonclinical rat findings is complete.
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927913, "Treatment of Iron Overload Requiring Chelation Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01927913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*